Kuros Biosciences
On a mission to ease this burden through superior biologics for better spinal fusions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | CHF6.0m | Private Placement VC |
| Total Funding | 000k | ||
| CHF | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 58 % | 242 % | 30 % | 87 % | 125 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (330 %) | (212 %) | (38 %) | (49 %) | (31 %) | (1 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (439 %) | (285 %) | (55 %) | (81 %) | (41 %) | (5 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 99 % | 36 % | 29 % | 17 % | 9 % |
Source: Company filings or news article
Related Content
Kuros Biosciences AG is a pioneering company in the field of bone healing and regeneration. The company specializes in developing advanced bone graft solutions that target and control bone healing processes. Kuros primarily serves healthcare providers, including hospitals and clinics, focusing on patients requiring bone grafts for spinal fusion and other orthopedic procedures. Operating in the medical technology market, Kuros leverages its proprietary technologies to create products like MagnetOs and Fibrin PTH, which are designed to improve patient outcomes by enhancing bone healing and reducing the risk of non-unions.
The business model of Kuros revolves around research and development, clinical trials, and commercialization of its innovative bone graft products. Revenue is generated through the sale of these products to healthcare institutions and through partnerships with other medical technology companies. Kuros also invests in continuous research to validate the efficacy and safety of its products, ensuring they meet the highest standards of medical care.
Kuros operates in a highly specialized niche within the broader medical technology sector, focusing on bone grafting solutions that offer significant advantages over traditional methods. The company's commitment to innovation and patient care positions it as a leader in the field of bone healing.
Keywords: bone graft, spinal fusion, orthopedic, MagnetOs, Fibrin PTH, bone healing, medical technology, healthcare, innovation, patient outcomes.
Tech stack
Investments by Kuros Biosciences
Edit